GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$32.63
-0.72 (-2.16%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 11, 2026
9d
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: GMAB shows positive signals but monitor for confirmation. Market pricing in 1.4% decline. Moderate conviction.
💡 BUY OPPORTUNITY: GMAB shows positive signals but monitor for confirmation. Market pricing in 1.4% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$20.60
Based on -9.1% avg growth
INTRINSIC VALUE TODAY
$12.79
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 22.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $32.63, which is considered fair relative to its 30-day fair value range of $32.11 to $34.14. The stock's valuation (Forward PE: 21.9) is in line with its historical norms (22.9). Remarkably, the market is currently pricing in an annual earnings decline of 1.4% over the next few years. This pessimistic expectation contrasts with the company's recent 107.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, GMAB is in a strong uptrend. Immediate support is located at $30.88, while resistance sits at $34.68.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $38.07 (+16.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMAB is in a strong uptrend. Immediate support is located at $30.88, while resistance sits at $34.68.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $38.07 (+16.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$32.11 -
$34.14
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.0%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($38.07)
Fair Price Analysis
30-Day Fair Range
$32.11 -
$34.14
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$30.88
Resistance Level
$34.68
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
21.93
Wall Street Target
$38.07
(+16.7%)
Revenue Growth (YoY)
17.4%
Earnings Growth (YoY)
107.6%
Profit Margin
41.2%
Valuation Discount vs History
-1.4% cheaper
PE vs Historical
21.9 vs 22.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.4%
(market-implied from PE analysis)
1-Year Target
$32.17
(-1%)
2-Year Target
$31.72
(-3%)
3-Year Target
$31.28
(-4%)
3-Yr Target (if PE normalizes)
(PE: 22→23)
$32.66
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: -22.2%)
$24.19
(+-26%)
Base:
(SPY PE: 21.9, Growth: -22.2%)
$23.79
(-27%)
Bear:
(PE: 18.6, Growth: -22.2%)
$20.22
(-38%)
📈
Valuation based on Current Earnings
Trailing PE: 14.38 | Current EPS (TTM): $2.29
Bull Case
$23.53
(-28%)
Analyst growth -35.0%, PE expands to 15.8
Base Case
$21.39
(-34%)
Market implied -35.0%, PE stable at 14.4
Bear Case
$22.39
(-31%)
Severe decline -20.0%, PE contracts to 12.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 21.9 to 22.9
Stabilization Target:
$34.07
(+4.4%)
PE Expansion Potential:
+4.4%
Last updated: February 01, 2026 5:00 PM ET
Data refreshes hourly during market hours. Next update: 6:00 PM
Data refreshes hourly during market hours. Next update: 6:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 59 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$117 | 59 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$140 | 59 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$42 | 64 BUY |
